Department of Obstetrics and Gynecology, University of Colorado School of Medicine, 12631 E. 17th Avenue, Aurora, CO 80045, USA.
Am J Obstet Gynecol. 2011 Mar;204(3):202.e1-4. doi: 10.1016/j.ajog.2011.01.014.
Available evidence now suggests that magnesium sulfate administered to mothers prior to early preterm delivery reduces the risk of cerebral palsy in surviving neonates. The American College of Obstetricians and Gynecologists along with the Society for Maternal-Fetal Medicine state that physicians who choose to administer magnesium sulfate for neuroprotection should do so in accordance with one of the larger randomized trials. Due to the heterogeneity of the methods, many clinicians may find it difficult to proceed with a therapeutic protocol that adheres to the available literature. Here, we present one reasonable approach that identifies the specific patients who qualify for magnesium sulfate therapy, and it outlines a treatment algorithm while addressing retreatment and concomitant tocolysis.
现有证据表明，在早产早期前给母亲注射硫酸镁可降低存活新生儿脑瘫的风险。美国妇产科医师学会和母胎医学学会指出，选择使用硫酸镁进行神经保护的医生应根据较大的随机试验之一进行治疗。由于方法的异质性，许多临床医生可能发现难以遵循现有的文献进行治疗方案。在这里，我们提出了一种合理的方法，确定了符合硫酸镁治疗条件的具体患者，并在解决重复治疗和伴随的宫缩抑制问题的同时概述了一个治疗算法。
